Search / Trial NCT06232616

Vitrectomy Combined With Intravitreal Dexamethasone Implant for Idiopathic Epiretinal Membrane With Macular Oedema

Launched by SHANGHAI EYE DISEASE PREVENTION AND TREATMENT CENTER · Jan 28, 2024

Trial Information

Current as of October 04, 2024

Enrolling by invitation

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * symptomatic patients aged 40 years or above with idiopathic stage 3-4 epiretinal membrane defined on the basis of spectral-domain optical coherence tomography classification;
  • * central retinal thickness \>300 µm;
  • * cystoid oedema within a 1 mm diameter range with the macular fovea as the center;
  • * ocular axial length less than 25.00 mm.
  • Exclusion Criteria:
  • * concomitant or previous macular diseases that may hinder visual improvement other than epiretinal membrane (e.g., age-associated macular degeneration, retinal vein occlusion, or diabetic macular oedema);
  • * previous vitreoretinal surgery or intravitreal injection history;
  • * history of glaucoma or optic neuropathy of any kind;
  • * patients with uncontrolled systemic diseases or infectious diseases;
  • * patients who took medicines that may have ocular side effects, such as glucocorticoid or hydroxychloroquine.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Shanghai, Shanghai, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0